1. Devendra A, Kohler M, Letsika M, Khooa H, et al.
   HIV viral suppression in children and adolescents two years after transition to dolutegravir: a multicentre cohort study.
   AIDS 2024.
   


2. Laufer N, Bouzas MB, Fernandez-Giuliano S, Zapiola I, et al.
   Pretreatment HIV-1 Resistance in Argentina: results from the second surveillance study following WHO guidelines (2019).
   AIDS Res Hum Retroviruses 2024.
   


3. Xu K, Chen J, Zhu M, Zhang X, et al.
   Exploring HIV-1 transmission features among older individuals in developed eastern China.
   AIDS Res Hum Retroviruses 2024.
   


4. Dube K, Perez-Brumer A, Patel H, Zhou C, et al.
   "This is actually a really unique moment in time": Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions - A Qualitative Interview Study in the United States.
   AIDS Res Hum Retroviruses 2024.
   


5. Guler E, Arikan Sarioglu A, Sultanoglu N, Suer K, et al.
   Molecular Epidemiology of HIV-1 Subtypes and Primary Antiretroviral Resistance Profiles in Northern Cyprus: First Data Series.
   AIDS Res Hum Retroviruses 2024.
   


6. Khayumbi J, Sasser L, McLaughlin T, Muchiri B, et al.
   Active tuberculosis is associated with depletion of HIV-specific CD4 and CD8 T cells in people with HIV.
   AIDS Res Hum Retroviruses 2024.
   


7. Sachdeva RK, Naidu G, Chauhan P, Kharbanda S, et al.
   CSF viral escape on HAART: Analysis from single tertiary care centre.
   AIDS Res Hum Retroviruses 2024.
   


8. Aggarwal NR, Nordwall J, Braun DL, Chung L, et al.
   Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.
   Clin Infect Dis 2024.
   


9. Griesel R, Banda CG, Zhao Y, Omar Z, et al.
   PHARMACOKINETICS OF SINGLE VERSUS DOUBLE-DOSE DOLUTEGRAVIR AFTER SWITCHING FROM A FAILING EFAVIRENZ-BASED REGIMEN.
   J Acquir Immune Defic Syndr 2024.
   


10. Gasca-Capote C, Lian X, Gao C, Roseto IC, et al.
    The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
    J Clin Invest 2024.
    


11. Pihl RMF, Smith-Mahoney EL, Olson A, Yuen RR, et al.
    Distinct subsets of Vdelta1 effector and Vdelta2 gammadelta T cells shift in frequency and are linked to plasma inflammatory markers during ART-suppressed HIV infection.
    J Infect Dis 2024.
    


12. Thiele RJ, Grunhagel B, Muenchhoff M, Pujantell-Graell M, et al.
    Magnitude of Type I Interferon Responses by Plasmacytoid Dendritic Cells After TLR7 Stimulation Is Associated With Human Immunodeficiency Virus Type 1 (HIV-1) Reservoir Sizes in Cisgender Women With HIV-1 on Antiretroviral Therapy.
    J Infect Dis 2024.
    


13. Shiau S, Zumpano F, Wang Z, Shah J, et al.
    Epigenetic Aging and Musculoskeletal Outcomes in a Cohort of Women Living With HIV.
    J Infect Dis 2024.
    


14. Serwin K, Scheibe K, Urbanska A, Aksak-Was B, et al.
    Phylodynamic evolution of HIV-1 A6 sub-subtype epidemics in Poland.
    J Med Virol 2024;96:e29482.
    


15. Del Pino M, Vorsters A, Joura EA, Doorbar J, et al.
    Risk factors for human papillomavirus infection and disease: A targeted literature summary.
    J Med Virol 2024;96:e29420.
    


16. Xu Y, Jiao K, Zhang Y, Huang S, et al.
    Behavioral intentions of self-isolation and informing close contacts after developing mpox-related symptoms among young men who have sex with men in China.
    J Med Virol 2024;96:e29470.
    


17. Fenton AD, Archin N, Turner A-M, Joseph S, et al.
    A novel high-throughput microwell outgrowth assay for HIV-infected cells.
    J Virol 2024.
    


18. Johnstone F.
    Picture an epidemic: contemporary culture and HIV.
    Lancet 2024.
    

Display articles in

• Abstract format
• Medline format